Schubert & Co’s AbbVie ABBV Stock Holding History

Schubert & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$209K	Sell	960 -15	-2%	-$3.33K	0.17%	68
2025 Q4	$223K	Sell	975 -262	-21%	-$59.7K	0.18%	63
2025 Q3	$286K	Sell	1,237 -116	-9%	-$23.6K	0.21%	57
2025 Q2	$251K	Buy	1,353 +205	+18%	+$38.1K	0.18%	64
2025 Q1	$241K	Buy	+1,148	New	+$223K	0.16%	56
2024 Q3	–	Sell	-1,164	Closed	-$212K	–	67
2024 Q2	$212K	Hold	1,164	–	–	0.18%	31
2024 Q1	$212K	Buy	+1,164	New	+$201K	0.18%	31
2023 Q3	–	Sell	-1,517	Closed	-$204K	–	31
2023 Q2	$204K	Sell	1,517 -48	-3%	-$7.04K	0.19%	35
2023 Q1	$249K	Sell	1,565 -407	-21%	-$62.2K	0.22%	29
2022 Q4	$319K	Buy	1,972 +81	+4%	+$12.4K	0.29%	20
2022 Q3	$254K	Buy	1,891 +12	+0.6%	+$1.72K	0.24%	25
2022 Q2	$288K	Buy	1,879 +1,727	+1,136%	+$264K	0.27%	19
2022 Q1	$25K	Buy	152 +40	+36%	+$5.81K	0.03%	73
2021 Q4	$15K	Buy	+112	New	+$13.2K	0.02%	81

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schubert & Co's ABBV Position: Q1 2026 in Review

Schubert & Co reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $3.33K and leaving 960 shares worth $209K. The position accounts for 0.17% of the portfolio, ranked #68.

Schubert & Co first reported a position in ABBV in Q4 2021 and has held it in 14 quarters since. The position peaked at $319K in Q4 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Schubert & Co held 960 shares of AbbVie worth $209K as of Q1 2026.
Schubert & Co sold 15 AbbVie shares in Q1 2026, an estimated $3.33K.
AbbVie made up 0.17% of Schubert & Co's portfolio in Q1 2026, its #68 holding.
Schubert & Co first reported a position in AbbVie in Q4 2021 and has held it in 14 quarters since.
Schubert & Co's AbbVie position peaked at $319K in Q4 2022.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Schubert & Co's 13F filing for Q1 2026, filed 29 Apr 2026.